Professor Yuwen Zhou: CAPCET Study Demonstrates a More Effective and Cost-Efficient First-Line Strategy for Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Professor Yuwen Zhou will present the CAPCET study, which focuses on first-line treatment for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer. By comparing modified CAPOX plus cetuximab with the conventional mFOLFOX6-based regimen, the study demonstrated significant therapeutic advantages. The results showed superior progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), while also offering reduced toxicity and better cost-effectiveness. These findings support the regimen as an efficient, safe, and economically favorable first-line treatment option for clinical practice.
Professor Haihong Wang: UNION TNT Study Highlights the Potential of Precision Combination Therapy for HER2-Expressing Locally Advanced Rectal Cancer
Professor Haihong Wang will present the UNION TNT study, which explores short-course radiotherapy combined with disitamab vedotin and immunochemotherapy for patients with HER2-expressing locally advanced rectal cancer. Preliminary findings demonstrate remarkable clinical benefit, with a pathological complete response (pCR) rate of 75% among patients who underwent surgery, while several additional patients achieved clinical complete response (cCR). These encouraging results underscore the significant potential of precision targeted combination therapy in the immunotherapy era to improve treatment efficacy while maximizing opportunities for organ preservation.
Professor Yi Yi Yu: Building a High-Quality IIT Research System at Zhongshan Hospital
This presentation provided an in-depth overview of Zhongshan Hospital's investigator-initiated trial (IIT) research system, highlighting its practical experience in infrastructure development, digital platforms, and talent cultivation. Through the implementation of the CREMS management platform, a dual electronic data capture (EDC) system, and the institutional innovation known as the "Zhongshan Ten Measures," the hospital has established a closed-loop quality management system covering the entire clinical research process. This model emphasizes standardized management spanning scientific review through to research translation, providing a robust foundation for medical innovation.
Pujiang Prostate Cancer Summit | Professor Jianming Guo: Breaking Through CRPC Resistance and Why Cytoreductive Surgery for Oligometastatic Disease Is Emerging as the Next Frontier
The 2026 Pujiang Prostate Cancer Summit was successfully held in Shanghai on June 26–27. Hosted by the Shanghai Anti-Cancer Association and organized by Fudan University Shanghai Cancer Center, the meeting brought together leading experts through keynote lectures, multidisciplinary (MDT) discussions, and live surgical demonstrations to highlight the latest advances in prostate cancer management. Among the meeting's major themes, personalized and precision treatment strategies attracted particular attention.
Pujiang Prostate Cancer Summit | Professor Dingwei Ye: Expanding Early Screening, Standardizing Care, and Advancing Clinical Research—Three Pillars to Narrow China’s Prostate Cancer Survival Gap
The 2026 Pujiang Prostate Cancer Summit was held in Shanghai on June 26–27 under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in genitourinary oncology to showcase the latest advances in standardized prostate cancer management and innovative treatment strategies.
Clear Horizons, Comprehensive Urologic Care | Professor Xin Yao: ADT Remains the Cornerstone of Prostate Cancer Management, While LHRH Antagonists Deliver Both Clinical Efficacy and Quality of Life
In this edition of Clear Horizons, Comprehensive Urologic Care, Professor Xin Yao from Tianjin Medical University Cancer Institute and Hospital discusses the mechanistic and clinical differences between LHRH agonists and antagonists, as well as practical strategies for managing ADT-related adverse events to maximize both treatment efficacy and patient quality of life.
APPLE 2026 | Prof. Stephen L. Chan: The Art and Science of Conversion Therapy in Cholangiocarcinoma
Cholangiocarcinoma is characterized by its high malignancy, with the majority of patients presenting with unresectable disease at initial diagnosis. In recent years, conversion therapy—which utilizes systemic treatment to downsize tumors—has emerged as a pivotal, offering select patients a pathway to curative-intent resection. However, striking the right balance between therapeutic efficacy and overtreatment remains a significant clinical challenge. At APPLE 2026, Prof. Stephen L. Chan, from the Chinese University of Hong Kong (CUHK) Faculty of Medicine, offered an in-depth analysis of these issues during an exclusive interview with our journal. Prof. Chen advocates for earlier genomic testing for alterations such as FGFR2 and IDH1, and proposes a multidimensional assessment framework combining radiology with circulating biomarkers like ctDNA and MRD to precisely identify the optimal surgical window. Furthermore, he recommends a stratified postoperative strategy guided by pathological response (MPR/pCR) to maximize recurrence-free survival.
APPLE 2026 | Prof. Masatoshi Kudo: Reconstructing Systemic-Locoregional Therapeutic Strategies for Hepatocellular Carcinoma in the Immuno-Oncology Era
As hepatocellular carcinoma (HCC) treatment enters the wave of immuno-oncology (IO) combinations, the paradigm of combining systemic therapy with locoregional treatments (LRT) is undergoing a qualitative leap—evolving from incremental gains to a fundamental reconstruction. Held from July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting convened in Shanghai, bringing together leading experts from across the Asia-Pacific, Europe, and North America to discuss novel strategies for liver cancer prevention and management.
APPLE 2026 | Academician Jia Fan Invites You to APPLE 2026 in Shanghai: Witness China’s Growing Global Leadership in Liver Cancer and Explore AI-Driven Innovation
From July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2026) will be held in Shanghai. Initiated by the Asia-Pacific Primary Liver Cancer Expert Association (APPLE), supported by the Shanghai Xinxin Medical Technology Development Foundation, and hosted by Zhongshan Hospital, Fudan University, the meeting will focus on the theme "Frontiers in the Diagnosis and Treatment of Primary Liver Cancer in the Era of Artificial Intelligence." Bringing together leading liver cancer experts from the Asia-Pacific region, Europe, and North America, APPLE 2026 will explore emerging strategies for liver cancer prevention and treatment. Following previous editions in 2012 and 2022, this marks the third time APPLE has been hosted in Shanghai, highlighting China's remarkable progress in healthcare, scientific research, and innovation over the past decade. Ahead of the meeting, Oncology Frontier spoke with Congress President Academician Jia Fan of Zhongshan Hospital, Fudan University, who reflected on APPLE's evolution, discussed the changing role of Chinese liver cancer specialists on the global stage, and shared his vision for how artificial intelligence (AI) will transform liver cancer care. Stay tuned for this landmark event.